Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Incidence and Outcomes of Treatment Refractory Diffuse Large B-Cell Lymphoma in the Immunochemotherapy Era

Matthew J Maurer, MS, Carrie A. Thompson, MD, Umar Farooq, MD, Tasha Lin, MD, Grzegorz S. Nowakowski, MD, Yi Lin, MD PhD, Ivana Micallef, MD, Anne Novak, PhD, William Macon, MD, Sergei Syrbu, MD, James Cerhan, MD PhD, Thomas E. Witzig, MD, Thomas M. Habermann, MD, Stephen Ansell, MD PhD, Brian K Link, MD

Blood (2015) 126 (23): 3992.

https://doi.org/10.1182/blood.V126.23.3992.3992

Published: 2015

Journal Articles

Comprehensive Analyses of Genetic Features Identify Coordinate Signatures in Diffuse Large B-Cell Lymphoma

Blood (2015) 126 (23): 3922.

https://doi.org/10.1182/blood.V126.23.3922.3922

Published: 2015

Journal Articles

VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human Waldenstrom Macroglobulinemia

Blood (2015) 126 (23): 703.

https://doi.org/10.1182/blood.V126.23.703.703

Published: 2015

Journal Articles

Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma

Muhammad A. Mir, Matthew J. Maurer, Steven C. Ziesmer, Susan L. Slager, Thomas Habermann, William R. Macon, Brian K. Link, Sergei Syrbu, Thomas Witzig, Jonathan W. Friedberg, Oliver Press, Michael LeBlanc, James R. Cerhan, Anne Novak, Stephen M. Ansell

Blood (2015) 125 (6): 992–998.

https://doi.org/10.1182/blood-2014-06-583369

Published: 2015

Includes: Supplemental data

Journal Articles

Methylation Patterns in Waldenströms Macroglobulinemia Cells That Are Inherently Resistant or Have Acquired Resistance to Bortezomib, Converge on the TP63 and Cepba Family of Transcription Factors

Aneel Paulus, MDMS, Xue Wang, PhD, Sharoon Akhtar, MPhil, Maja Kuranz-Blake, B.S., Anne Novak, PhD, Stephen M Ansell, MD, PhD, Morie A Gertz, MD, Robert A Kyle, MD, Peter Martin, MD, Morton Coleman, MD, Sikander Ailawadhi, MD, Asher Chanan-Khan, MD, Kasyapa S. Chitta, PhD

Blood (2014) 124 (21): 3551.

https://doi.org/10.1182/blood.V124.21.3551.3551

Published: 2014

Journal Articles

A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study

Blood (2013) 122 (21): 76.

https://doi.org/10.1182/blood.V122.21.76.76

Published: 2013

Journal Articles

IL-21 and IL-6 Mediate Interactions Between T Cells and Malignant B Cells in the Bone Marrow Microenvironment in Waldenstrom's Macroglobulinemia

Lucy S. Hodge, PharmD, Ph.D., Steve Ziesmer, Frank J Secreto, Ph.D., Zhi-Zhang Yang, MD, Anne Novak, Morie Abraham A Gertz, MD, Stephen M Ansell, M.D., Ph.D.

Blood (2012) 120 (21): 1554.

https://doi.org/10.1182/blood.V120.21.1554.1554

Published: 2012

Journal Articles

Interplay Between Histone Deacetylases (HDACs) and STAT3: Mechanism of Activated JAK/STAT3 Oncogenic Pathway in ABC (Activated B-cell) Type Diffuse Large B Cell Lymphoma.

Mamta Gupta, Mary Stenson, Terra Lasho, Ayalew Tefferi, Anne Novak, Stephen M. Ansell, Thomas E. Witzig

Blood (2009) 114 (22): 925.

https://doi.org/10.1182/blood.V114.22.925.925

Published: 2009

Journal Articles

Malignant B Cell-Derived TGF-β Controls the Generation of T H 1, T H 17 and T reg Cells in the Tumor Microenvironment of B-Cell Non-Hodgkin Lymphoma (NHL).

Zhi-Zhang Yang, MD, Anne Novak, PhD, Thomas E. Witzig, Stephen M. Ansell

Blood (2008) 112 (11): 1551.

https://doi.org/10.1182/blood.V112.11.1551.1551

Published: 2008

Journal Articles

Genetic Variation in Genes That Regulate T-Cell Differentiation and Function Is Associated with An Increased Risk of Developing B-Cell Non- Hodgkin Lymphoma

Stephen M. Ansell, Anne Novak, Zhi-Zhang Yang, Zachary S. Fredericksen, Alice H. Wang, Neil Kay, Mark Liebow, Ahmet Dogan, Timothy G. Call, Thomas Witzig, Thomas M. Habermann, Susan L. Slager, James R. Cerhan

Blood (2008) 112 (11): 3762.

https://doi.org/10.1182/blood.V112.11.3762.3762

Published: 2008

Journal Articles

Elevated Expression of GPR34 and Its Association with a Novel Translocation T(X;14)(p11;q32) Involving IGHS and GPR34 in MALT Lymphoma.

Anne Novak, Takashi Akasaka, Michelle Manske, Mamta Gupta, Thomas Witzig, Martin JS Dyer, Ahmet Dogan, Ellen Remstein, Stephen Ansell

Blood (2008) 112 (11): 2251.

https://doi.org/10.1182/blood.V112.11.2251.2251

Published: 2008

Journal Articles

Phase 1 Clinical Study of Atacicept in Patients with Relapsed and Refractory B-Cell Lymphoma.

Stephen Ansell, Thomas E. Witzig, Anne Novak, David James, Inwards, Luis Porrata, A. Ythier, L. Ferrande, I. Nestorov, T. DeVries, Eric Sievers

Blood (2006) 108 (11): 2722.

https://doi.org/10.1182/blood.V108.11.2722.2722

Published: 2006

Journal Articles

Rapamycin Enhances the Cytotoxicity of Bortezomib and Rituximab on Mantle Cell Lymphoma (MCL) Cell Lines.

Laila K. Ismail, MD, Michael Timm, BS, Anne Novak, PhD, Mary Stenson, BS, Stephen M. Ansell, MD, PhD, Thomas E. Witzig, MD

Blood (2005) 106 (11): 2411.

https://doi.org/10.1182/blood.V106.11.2411.2411

Published: 2005

Journal Articles

Absolute Lymphocyte Count and CD4 Count Predict a Superior Progression-Free Survival in Non-Hodgkin Lymphoma Patients Treated with Rituximab and Interleukin-12.

Cristina Joao, MD, Luis F. Porrata, MD, Thomas Witzig, MD, Paul Kurtin, Ivana Micallef, MD, Svetomir N. Markovic, MD, PhD, Charles Erlichman, MD, Anne Novak, Stephen M. Ansell, MD, PhD

Blood (2005) 106 (11): 1495.

https://doi.org/10.1182/blood.V106.11.1495.1495

Published: 2005

NARROW

Incidence and Outcomes of Treatment Refractory Diffuse Large B-Cell Lymphoma in the Immunochemotherapy Era

Comprehensive Analyses of Genetic Features Identify Coordinate Signatures in Diffuse Large B-Cell Lymphoma

VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human Waldenstrom Macroglobulinemia

Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma

Methylation Patterns in Waldenströms Macroglobulinemia Cells That Are Inherently Resistant or Have Acquired Resistance to Bortezomib, Converge on the TP63 and Cepba Family of Transcription Factors

A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study

IL-21 and IL-6 Mediate Interactions Between T Cells and Malignant B Cells in the Bone Marrow Microenvironment in Waldenstrom's Macroglobulinemia

Interplay Between Histone Deacetylases (HDACs) and STAT3: Mechanism of Activated JAK/STAT3 Oncogenic Pathway in ABC (Activated B-cell) Type Diffuse Large B Cell Lymphoma.

Malignant B Cell-Derived TGF-β Controls the Generation of T H 1, T H 17 and T reg Cells in the Tumor Microenvironment of B-Cell Non-Hodgkin Lymphoma (NHL).

Genetic Variation in Genes That Regulate T-Cell Differentiation and Function Is Associated with An Increased Risk of Developing B-Cell Non- Hodgkin Lymphoma

Elevated Expression of GPR34 and Its Association with a Novel Translocation T(X;14)(p11;q32) Involving IGHS and GPR34 in MALT Lymphoma.

Phase 1 Clinical Study of Atacicept in Patients with Relapsed and Refractory B-Cell Lymphoma.

Rapamycin Enhances the Cytotoxicity of Bortezomib and Rituximab on Mantle Cell Lymphoma (MCL) Cell Lines.

Absolute Lymphocyte Count and CD4 Count Predict a Superior Progression-Free Survival in Non-Hodgkin Lymphoma Patients Treated with Rituximab and Interleukin-12.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only